)
Anamaria Sudarov, PhD
Managing Director
Wells Fargo
Anamaria Sudarov is a managing director for the Healthcare Investment Banking division of Wells Fargo, focused on the Biopharma sector. Anamaria has 13+ years of experience in investment banking focused on Pharma
and Biotech sectors. A few of her notable transactions include Seagen’s sale to Pfizer, Chinook Therapeutics’ sale to Novartis, CTI Biopharma’s sale to SOBI, and Epizyme’s sale to Ipsen.
Prior to joining Wells Fargo in 2024, Anamaria worked at MTS Health Partners where she served as a managing director. Prior to MTS, she worked at Credit Suisse in their Large Cap Biotech Equity Research group.
Anamaria holds a Ph.D. in developmental genetics, with a focus in neurology and genetics from New York University/Memorial Sloan Kettering and worked as a Postdoctoral Fellow at Weill Cornell Medical College, Brain and Mind Research Institute.
She is based in New York.
Sessions
-
22-Jun-202625ABCClosing Deals in Uncertain Times
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}